2428381-49-9
2428381-49-9
Chemical Structure
Pulocimab
Synonym(s): AK109
- CAS No.: 2428381-49-9
- Molecular Weight:(143.721 kDa)
SMILES: [Pulocimab]
Biological Activity: Pulocimab (AK109) is an orally active PPARα/γ dual activator with EC50 values of 48 nM and 67 nM, respectively. Pulocimab reduces plasma glucose, improves dyslipidemia, lowers total cholesterol, and raises HDL cholesterol. Pulocimab binds VEGFR2 and blocks VEGF/VEGFR2 signaling, inhibiting angiogenesis, endothelial cell migration, and tumor cell proliferation. Pulocimab can be used for research on type 2 diabetes with dyslipidemia and advanced or metastatic solid tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pulocimab | 98.42% | Pulocimab (AK109) is an orally active PPARα/γ dual activator with EC50 values of 48 nM and 67 nM, respectively. Pulocimab reduces plasma glucose, improves dyslipidemia, lowers total cholesterol, and raises HDL cholesterol. Pulocimab binds VEGFR2 and blocks VEGF/VEGFR2 signaling, inhibiting angiogenesis, endothelial cell migration, and tumor cell proliferation. Pulocimab can be used for research on type 2 diabetes with dyslipidemia and advanced or metastatic solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Umeno H, et al. AK109, a Novel Propionic Acid Derivative Non-TZD Dual PPAR alpha/gamma Agonist, That Has More Potential To Reduce Glucose and To Improve Dyslipidemia Than Rosiglitazone or Pioglitazone [abstract]. Presented at the American Diabetes Association Annual Scientific Meeting; [Year]; [Location]. Abstract 2173-PO.
- [2]. Zheng Y, et al. First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients with advanced or metastatic solid tumors. ESMO Open. 2023;8(3):101156.
